Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0851
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients ; volume:69 ; number:5 ; day:12 ; month:2 ; year:2020 ; pages:771-777 ; date:5.2020
Cancer immunology immunotherapy ; 69, Heft 5 (12.2.2020), 771-777, 5.2020
- Urheber
-
Hurkmans, Daan P.
Kuipers, Merian E.
Smit, Jasper
Marion, Ronald van
Mathijssen, Ron H. J.
Postmus, Piet E.
Hiemstra, Pieter S.
Aerts, Joachim G. J. V.
Thüsen, Jan H. von der
Burg, Sjoerd H. van der
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-020-02506-x
- URN
-
urn:nbn:de:101:1-2020070513511392783167
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hurkmans, Daan P.
- Kuipers, Merian E.
- Smit, Jasper
- Marion, Ronald van
- Mathijssen, Ron H. J.
- Postmus, Piet E.
- Hiemstra, Pieter S.
- Aerts, Joachim G. J. V.
- Thüsen, Jan H. von der
- Burg, Sjoerd H. van der
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
CD8+CD38+, CD8+HLA-DR+ : Stellenwert dieser Lymphozytensubpopulationen als Surrogatmarker bei der HIV-Infektion
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
PD-L1 Expression und CD8 positive zytotoxische Lymphozyten in mesenchymalen Tumoren
HLA-DRB5 promotes immune thrombocytopenia via activating CD8 + T cells
CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma
Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC
Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity
Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression
A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
CD8+CD38+, CD8+HLA-DR+ : Stellenwert dieser Lymphozytensubpopulationen als Surrogatmarker bei der HIV-Infektion
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
PD-L1 Expression und CD8 positive zytotoxische Lymphozyten in mesenchymalen Tumoren
HLA-DRB5 promotes immune thrombocytopenia via activating CD8 + T cells
CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma
Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC
Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity
Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression
A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
CD8+CD38+, CD8+HLA-DR+ : Stellenwert dieser Lymphozytensubpopulationen als Surrogatmarker bei der HIV-Infektion
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
PD-L1 Expression und CD8 positive zytotoxische Lymphozyten in mesenchymalen Tumoren
HLA-DRB5 promotes immune thrombocytopenia via activating CD8 + T cells
CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma
Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC
Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity
Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression